1-Abdollah F, Dalela D, Haffner MC, Culig Z, Schalken J. The Role of Biomarkers and Genetics in the Diagnosis of Prostate Cancer. Eur Urol Focus 2015 Sep;1(2):99-108.
2-Moradi A, Srinivasan S, Clements J1, Batra J. Beyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment. Cancer Metastasis Rev 2019 Sep;38(3):333-346.
3-Nevo A, Navaratnam A, Andrews P. Prostate cancer and the role of biomarkers. Abdom Radiol (NY) 2019 Nov 13. doi: 10.1007/s00261-019-02305-8. [Epub ahead of print]
4-Bernal-Soriano MC, Parker LA, López-Garrigos M, Hernández-Aguado I, Caballero-Romeu JP, et al. Factors associated with false negative and false positive results of prostate-specific antigen (PSA) and the impact on patient health: Cohort study protocol. Medicine (Baltimore) 2019 Oct;98(40):e17451. doi: 10.1097/MD.0000000000017451.
5-Horwich A, Parker C, de Reijke T, Kataja V; ESMO Guidelines Working Group. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013 Oct;24 Suppl 6:vi106-14. doi: 10.1093/annonc/mdt208. Epub 2013 Jun 27.
6-Carroll PR, Vickers AJ. Point/Counterpoint: early detection of prostate cancer: do the benefits outweigh the consequences? J Natl Compr Canc Netw 2014 May;12(5 Suppl):768-71.
7-Kumar N, Yadav S, Kumar S, Saurav K, Prasad V, Vasudeva P. Comparison of percentage free PSA, MRI and Ga PSMA PET scan for diagnosing cancer prostate in men with PSA between 4 and 20 ng/ml. Indian J Urol 2019 Jul-Sep;35(3):202-207.
8-Verma A, St Onge J, Dhillon K, Chorneyko A. PSA density improves prediction of prostate cancer. Can J Urol 2014 Jun;21(3):7312-21.
9-Nordström T, Akre O, Aly M, Grönberg H, Eklund M4. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer Prostatic Dis 2018 Apr;21(1):57-63.
10-Wu ZY, Yang C, Luo J, Deng SL, Wu B, Chen M. Establishment of reference intervals for serum [-2]proPSA (p2PSA), %p2PSA and prostate health index in healthy men. Onco Targets Ther 2019 Aug 13;12:6453-6460.
11-Ito K, Yamamoto T, Ohi M, Kurokawa K, Suzuki K, Yamanaka H. Free/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1 to 10.0 ng/mL. Urology 2003 Apr;61(4):760-4.
12-Caliskan S. Diagnostic efficacy of free prostate-specific antigen/total prostate-specific antigen ratio for the diagnosis of prostate cancer in low concentration (≤4 ng/ml) and intermediate levels of total prostate-specific antigen (4.01-10.0 ng/ml). J Cancer Res Ther 2017 Apr-Jun;13(2):279-283.
13-Koizumi M, Motegi K, Koyama M, Terauchi T, Yuasa T, Yonese J. Diagnostic performance of a computer-assisted diagnosis system for bone scintigraphy of newly developed skeletal metastasis in prostate cancer patients: search for low-sensitivity subgroups. Ann Nucl Med 2017 Aug;31(7):521-528.
14-Thomsen FB, Westerberg M, Garmo H, Robinson D, Holmberg L, Ulmert HD, Stattin P. Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study. PLoS One 2020 Jan 29;15(1):e0228447. doi: 10.1371/journal.pone.0228447. eCollection 2020.
15-Valero J, Peleteiro P, Henríquez I, Conde A, Piquer T, Lozano A, et al. Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR). Clin Transl Oncol 2020 Jan 27. doi: 10.1007/s12094-019-02274-w. [Epub ahead of print]
16-Kouriefs C, Sahoyl M, Grange P, Muir G. Prostate specific antigen through the years. Arch Ital Urol Androl 2009 Dec;81(4):195-8.
17-Reed AB, Parekh DJ. Biomarkers for prostate cancer detection. Expert Rev Anticancer Ther 2010 Jan;10(1):103-14. doi: 10.1586/era.09.168.
18-Vezyraki P, Vlachaki A, Baltogiannis D, Batistatou A, Tsampalas S, V Simos Y. Impact of total PSA and percent free PSA in the differentiation of prostate disease: a retrospective comparative study implicating neoplastic and non-neoplastic entities. J BUON 2019 Sep-Oct;24(5):2107-2113.
19-Esfahani M, Ataei N, Panjehpour M. Biomarkers for evaluation of prostate cancer prognosis. Asian Pac J Cancer Prev 2015;16(7):2601-11.
20-Tanguay S, Bégin LR, Elhilali MM, Behlouli H, Karakiewicz PI, Aprikian AG. Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection. Urology 2002 Feb;59(2):261-5.
21-Erol B, Gulpinar MT, Bozdogan G, Ozkanli S, Onem K, Mungan G, et al. The cutoff level of free/total prostate specific antigen (f/t PSA) ratios in the diagnosis of prostate cancer: a validation study on a Turkish patient population in different age categories. Kaohsiung J Med Sci 2014 Nov;30(11):545-50. doi: 10.1016/j.kjms.2014.03.008. Epub 2014 Apr 20.
22-Catalona WJ, Partin AW, Slawin KM, Naughton CK, Brawer MK, Flanigan RC, et al. Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial. Urology 2000,55(3):372-6.
23-NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)Prostate Cancer. Versión 2.2019; 2019. NCCN org.
24-Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2017 Apr;71(4):618-629.
25-Björk T, Lilja H, Christensson A. The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer. BJU Int 1999 Dec;84(9):1021-7.
26-Agnihotri S, Mittal RD, Ahmad S, Mandhani A. Free to total serum prostate specific antigen ratio in symptomatic men does not help in differentiating benign from malignant disease of the prostate. Indian J Urol 2014 Jan;30(1):28-32.
27-Huyghe E, Soulie M, Tollon C, Escourrou G, Pontonnier F, Plante P. Value of free PSA/total PSA ratio in therapeutic decisions in the case of a single positive biopsy of the prostate. Prog Urol 1999 Apr;9(2):281-7.
28-Sevcenco S, Grubmüller B, Sonneck-Koenne C, Ahmadi Y, Knoll P, Floth A, et al. Bone Scintigraphy in Staging of Newly Diagnosed Prostate Cancer in Regard of Different Risk Groups. Asia Ocean J Nucl Med Biol 2019 Spring;7(2):149-152.
29-Suh CH, Shinagare AB, Westenfield AM, Ramaiya NH, Van den Abbeele AD, Kim KW. Yield of bone scintigraphy for the detection of metastatic disease in treatment-naive prostate cancer: a systematic review and meta-analysis. Clin Radiol 2018 Feb;73(2):158-167.
30-Wei RJ, Li TY, Yang XC, Jia N, Yang XL, Song HB. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.Genet Mol Res 2016 Jun 3;15(2).
31-Ozu C, Nakashima J, Horiguchi Y, Oya M, Ohigashi T, Murai M. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer. Int J Urol 2008 May;15(5):419-22.
32-Shepherd KL, Cool P, Cribb G. Prognostic indicators of outcome for patients with skeletal metastases from carcinoma of the prostate.Bone Joint J 2018 Dec;100-B(12):1647-1654.
33-Moslehi M, Cheki M, Salehi-Marzijarani M, Amuchastegui T, Gholamrezanezhad A. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer. Rev Esp Med Nucl Imagen Mol 2013 Sep-Oct;32(5):286-9.
34-Singh OP, Yogi V, Redhu P, Ghori HU, Pareek A, Lal N. Role of serum prostate-specific antigen as predictor for bone metastases in newly diagnosed prostate cancer. J Cancer Res Ther 2019Mar;15(Supplement):S39-S41.
35-Al-Ghazo MA, Ghalayini IF, Al-Azab RS, Bani-Hani I, Barham A, Haddad Y. Do all patients with newly diagnosed prostate cancer need staging radionuclide bone scan? A retrospective study. Int Braz J Urol 2010 Nov-Dec;36(6):685-91; discussion 691-2.